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Vasopressin (arg8-vasopressin) and oxytocin are closely related nonapeptide
hormones, synthesized as pre-hormones in the magnocellular neurons of the paraventricular
and supraoptic nuclei of the hypothalamus. Vasopressin and oxytocin are secreted in response to a
variety of physiological stimuli, serving such different functions as controlling water balance, milk
ejection, uterine contraction, mood, and parental behavior (Lechan and Toni, 2000; Costa et al.,
2014a).
MUSCLE AS A TARGET OF NEUROHYPOPHYSEAL HORMONES
Skeletal muscle or myogenic precursors have never been considered, until recently, as targets
of neurohypophyseal hormones. However, very early evidence was provided by Wakelam and
collaborators, who showed some mild effects of vasopressin on carbohydrate metabolism in
myoblasts (Wakelam and Pette, 1982; Wakelam et al., 1987). These initial observations were
corroborated by later studies showing that stimulation of primary chick embryo myoblasts or
murine L6 and L5 myogenic cell lines with vasopressin, oxytocin, their analogs and antagonists
resulted in the structure- and concentration-dependent activation of phospholipase C (PLC)
signaling, the stimulation ofmyogenic differentiation, and the hypertrophy of newly formedmuscle
fibers (Teti et al., 1993; Nervi et al., 1995). Worth noting, PLC activates Protein Kinase C family
members, among which the theta isoform plays an important role in both muscle differentiation
and disease (Marrocco et al., 2014, 2017; Lozanoska-Ochser et al., 2018). The potent pro-myogenic
effect of vasopressin was further characterized in myogenic cells cultured in a serum-free medium,
a “clean” experimental model that allowed us to establish that L6 myogenic cells express the
vasopressin V1a receptor (V1a-R) and that vasopressin elicits a complex signal transduction
response in these cells (Minotti et al., 1998; Scicchitano, 2002, 2005; Naro et al., 2003; Toschi et al.,
2011; Costa et al., 2014b). Moreover, it was found that V1a-R expression is modulated during the
differentiation of L6 cells, probably in a post-translational manner (Alvisi et al., 2008).
Studies from other laboratories highlighted the presence of functional oxytocin receptors
(OT-R) in humanmyoblasts derived from postnatal satellite cells (Breton et al., 2002), and in C2C12
myogenic cells which respond to oxytocin by activating the calcium–CaMKK–AMPK pathway (Lee
et al., 2008). A recent in vitro study showed that C2C12 myoblasts express not only OT-R but also
oxytocin and that the expression of both products increases upon myogenic differentiation of the
cells (Berio et al., 2017). Furthermore, myotubes treated with 17β-estradiol overexpress oxytocin
and OT-R genes by approximately 3- and 29-fold, respectively (Berio et al., 2017).
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While cell cultures provide useful models to define, under
controlled conditions, the effects of vasopressin or oxytocin
on myogenic differentiation at the molecular level, in vivo
data support the idea that both neurohypophyseal hormones
play physiological roles in skeletal muscle. Indeed, a role for
neurohypophyseal hormones in prenatal muscle development
was first suggested by the presence of immunoreactive
vasopressin in human fetal and neonatal skeletal muscle
(Smith et al., 1992). Moreover, a >120-fold increase in oxytocin
expression was observed in bovine muscle during early to
mid-fetal calf development, coincident with active myofiber
formation (De Jager et al., 2011), findings in keeping with the
above reported in vitro data.
In an in vivo murine experimental model, we reported that
V1a-R expression, measurable under basal conditions in muscle,
was strongly up-regulated in the early phase of regeneration
(9 h after injury) and gradually decreased in the following days,
along with the regeneration process. In this model, vasopressin
administration promoted muscle regeneration. Furthermore,
overexpression of V1a-R in muscle sufficed to dramatically
enhance post-injury muscle regeneration, without administering
exogenous vasopressin (Toschi et al., 2011). In an in vivo
mouse model of tumor necrosis factor (TNF)-inhibited muscle
regeneration, the administration of vasopressin rescued the
inhibitory effect of TNF, likely through a mechanism involving
themodulation of HSP70 levels (Moresi et al., 2009). Again, TNF-
mediated muscle atrophy was rescued by the overexpression of
the V1a-R in vivo (Costa et al., 2014b).
Altogether, the in vivo evidence supports the notion that both
vasopressin and oxytocin have potent effects, in the development,
regeneration and homeostasis of skeletal muscle.
Further insights came from studies conducted in aged mice
(Elabd et al., 2014). The authors focused on the reduced
muscle regeneration and muscle atrophy (sarcopenia) occurring
in aging. While it is known that aging is accompanied by
reduced physiological levels of sex steroids, the authors found
that circulating oxytocin level is also reduced. Interestingly,
satellite cells from aged animals exhibited a significantly lower
OT-R expression than those from young animals. Moreover,
comparing young and aged mice treated with an oxytocin
selective antagonist or with exogenous oxytocin, respectively,
the authors demonstrated that oxytocin is required for efficient
muscle regeneration (Elabd et al., 2014). The impaired muscle
regeneration of aged mice was shown to depend primarily
upon reduced proliferation of satellite cells, a phenomenon
rescued by exogenous oxytocin administration. The oxytocin
effect on satellite cell proliferation was reported to be mediated
by the MAPK/ERK pathway (Elabd et al., 2014). In line
with the above findings, muscle regeneration in oxytocin
KO mice was severely compromised. Young oxytocin KO
mice displayed a premature decline in muscle regeneration,
as well as muscle fibrosis and fat infiltration, showing a
muscle phenotype characteristic of sarcopenia (Elabd et al.,
2014).
Therefore, both neurohypophyseal hormones appear to
regulate positively muscle homeostasis in different models:
oxytocin, in the aging and KOmouse models (Elabd et al., 2014);
and vasopressin, in injured muscle or TNF-induced muscle
wasting (Moresi et al., 2009; Toschi et al., 2011; Costa et al.,
2014b).
The apparent overlapping between the observed effects of the
two neurohypophyseal hormones in the regulation of muscle
differentiation and trophism may depend on the fact that both
V1a-R and OT-R cross-bind their ligands, albeit with different
affinities (Barberis et al., 1998; Gupta et al., 2008). Furthermore,
the results obtained in the myogenic L6 cell line used as
an experimental tool to show the effect of neurohypophyseal
hormones probably depend on a peculiar expression of the
receptors for these hormones, in comparison to other myogenic
cell types.
MUSCLE TISSUE AS A SOURCE OF
VASOPRESSIN AND OXYTOCIN
Interestingly, the possibility that myogenic cells express one of
the neurohypophyseal hormones, as suggested by the pioneering
results of Smith in prenatal human muscle for vasopressin
(Smith et al., 1992), was recently proposed again (Berio
et al., 2017), with regard to oxytocin and OT-R. Based on
these observations, muscle can thus be added to the list of
previously unrecognized sites of oxytocin expression, such
as testes, ovaries, heart and lungs (Assinder et al., 2000;
Jankowski et al., 2004; Kiss and Mikkelsen, 2005; Gutkowska
and Jankowski, 2012). Further results supporting this hypothesis,
were obtained in studies aimed to investigate the mechanisms
triggered by the administration of steroids used to increase
muscle mass in livestock farming. Cattle regularly treated with
anabolizing agents displayed dramatically enhanced oxytocin
mRNA expression in skeletal muscle, accompanied by a ∼50-
fold higher level of circulating oxytocin (De Jager et al.,
2011). Intriguingly, the authors provided evidence that the
hypertrophying effect of anabolic steroids is prevalently mediated
by OT-R signaling. Furthermore, in a more recent study, Divari
reported that serum levels of oxytocin increased dramatically
in cattle regularly treated with 17β-estradiol, but not with
either dexamethasone or placebo. This administration of 17β-
estradiol also resulted in increased (33-fold) skeletal muscle
expression of the oxytocin-precursor mRNA (Divari et al.,
2013). Increased expression of the oxytocin-precursor mRNA
was also found in the muscle of sheep subjected to chronical
treatment with a combination of 17β-estradiol and the synthetic
androgen trenbolone acetate (TBA). Also the circulating oxytocin
level increased in steroid-treated sheep compared to placebo-
treated controls (Kongsuwan et al., 2012). Together, the above
studies indicate a correlation between the steroid-inducedmuscle
hypertrophy and the increased expression of both oxytocin and
OT-R in skeletal muscle.
The mechanisms underlying regulation by steroids of
oxytocin expression remain to be fully elucidated. The oxytocin
promoter does not possess a classical Estrogen Response
Element, whereas it has a high affinity binding-site for nuclear
orphan receptors/estrogen related receptor alpha (ERRα). Koohi
reported that the estrogen dependent control of the oxytocin
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promoter is independent of classical Estrogen Receptor (ER)
binding, but requires a functional ERRα (Koohi et al.,
2005). These authors further demonstrated that the estrogenic
stimulation of the OT-R occurs through the ERK/MAPK-
mediated stimulation of the transcriptional activity of ERRα.
The up-regulation of oxytocin expression by this non-classical
mechanism may, in turn, sustain an autocrine feed-forward
oxytocin/OT-R loop which amplifies the response to oxytocin, as
shown in bone (Colaianni et al., 2012; Berio et al., 2017).
Worth noting, exercise (i.e., muscle contraction) represents
a physiological stimulus increasing the levels of circulating
neurohypophyseal hormones, as well as their expression (or the
expression of their receptors) in several tissues beside skeletal
muscle (Martins et al., 2005). Based on several studies in man
and other mammals, it is clear that exercise induces a five-
fold increase in the circulating levels of vasopressin (Melin
et al., 1980; Convertino et al., 1981; Alexander et al., 1991).
This increase, associated to the beneficial effects of exercise on
muscle homeostasis, suggests a model whereby physical activity
stimulates muscle secretion of the neurohypophyseal hormones
and induces a generalized sensitization to these factors through
the up-regulation of their receptors in various districts. An
exercise-mediated increase in vasopressin and/or oxytocin could
ultimately contribute to maintaining muscle homeostasis and
add to the additional benefits of exercise, including an increased
life span and general well-being.
FINAL REMARKS
The in vitro and in vivo studies discussed above suggest that
skeletal muscle is a target of neurohypophyseal hormones, which
regulate muscle homeostasis and function in both physiological
and pathological conditions. On the other hand, skeletal muscle
has been recognized as the source of a wide range of circulating
factors, namely myokines, which regulate a number of different
functions with paracrine or endocrine mechanisms (Pedersen
and Febbraio, 2008; Hoffmann and Weigert, 2017). In the light
of its abundance in the organism, skeletal muscle may thus be
regarded as the largest endocrine gland in the body. In this article,
we discuss in vitro and in vivo studies showing that oxytocin
is synthesized by muscle and that its secretion significantly
contributes to the level of circulating hormones. This activity
appears to be central to the mechanisms which regulate muscle
homeostasis, to contribute to muscle hypertrophic responses
and to be altered in atrophic conditions. As a whole, this
evidence suggests that OT and AVP be considered as potential
myokines. In addition, these considerations suggest a potential
therapeutic use of these molecules, along with more selective
and potent analogs, in atrophic and muscle wasting conditions,
such as sarcopenia and cachexia, and as a tool in adjuvant
therapies against muscular dystrophies and neuromuscular
diseases.
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